

**Supplementary Table 1. Subsequent treatments after daratumumab therapy**

Subsequent treatments	Overall (n = 50)	ALC <sup>D56</sup> > 700/ $\mu$ L (n = 39)	ALC <sup>D56</sup> $\leq$ 700/ $\mu$ L (n = 11)
IMiDs <sup>a</sup>	7 (14.0)	6 (15.4)	1 (9.1)
PIs <sup>a</sup>	7 (14.0)	7 (17.9)	0
Cytotoxic chemotherapy	7 (14.0)	5 (12.8)	2 (18.2)
No treatment	2 (4.0)	2 (5.1)	0 (0.0)
Death	10 (20.0)	4 (10.3)	6 (54.5)
Others	1 (2.0)	1 <sup>b</sup> (2.6)	0
Daratumumab <sup>c</sup>	16 (32.0)	14 (35.9)	2 (18.2)

Values are presented as number (%).

ALC<sup>D56</sup>, absolute lymphocyte counts at the day prior to the third cycle of daratumumab; IMiD, immunomodulatory drug; PI, proteasome inhibitor.

<sup>a</sup>No patient was treated with combination therapy with IMiDs and PIs.

<sup>b</sup>One patient was diagnosed with myelodysplastic syndrome during daratumumab therapy.

<sup>c</sup>Patients who responded to daratumumab continued the therapy.